memantine hydrochloride and donepezil hydrochloride

FDA Drug Profile — memantine hydrochloride and donepezil hydrochloride, Namzaric

memantine hydrochloride and donepezil hydrochloride is listed in the FDA National Drug Code directory with 10 NDC codes, marketed under brand names including memantine hydrochloride and donepezil hydrochloride, Namzaric. Available dosage forms: capsule, extended release, capsule.

Drug details

Generic Name
memantine hydrochloride and donepezil hydrochloride
Brand Names
memantine hydrochloride and donepezil hydrochloride, Namzaric
Application Number
ANDA216901
Sponsor
Vitruvias Therapeutics, Inc.
NDC Codes
10
Dosage Forms
CAPSULE, EXTENDED RELEASE, CAPSULE
Routes
ORAL
Active Ingredients
MEMANTINE HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE

Indications and Usage

1 INDICATIONS AND USAGE NAMZARIC is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily. NAMZARIC is a combination of memantine hydrochloride, an NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor, indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily. ( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.